Codexis, Inc. (Nasdaq:CDXS), a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, tomorrow will celebrate 10 years as a company. Since its founding in 2002, the company has developed, improved and applied its CodeEvolver™ Directed Evolution platform across a broad spectrum of industries. Codexis technology has enabled significant improvements in manufacturing processes for pharmaceutical intermediates for some of the world’s largest blockbuster drugs, and has created customized advanced enzymes and organisms for use in industrial biofuels, renewable chemicals, and carbon capture applications.
“We have accomplished a tremendous amount in the past 10 years, including achieving key breakthroughs in our directed evolution technology, delivering products to a wide array of pharmaceutical clients, and establishing a successful partnership with Shell leading to major advancements in our biofuels technology,” said Peter Strumph, Interim Chief Executive Officer. “In the next 10 years, we believe our technology leaves us well positioned to continue to grow our pharmaceuticals business and be a significant player in the emerging renewable fuels and chemicals fields. Our success, past and future, can be credited to our dedicated team of employees in the U.S., Europe and Asia. Their ability to innovate and consistently deliver results is unsurpassed.”
At a 10 th anniversary event at Codexis headquarters in Redwood City, employees and distinguished guests will celebrate the company’s achievements, and management will lay out a vision for the next 10 years. Some of the specific accomplishments and awards Codexis has achieved include:
- Two EPA Presidential Green Chemistry Awards for clean manufacturing processes for market-leading therapeutics for diabetes and heart disease
- Draper Prize from National Academy of Engineering (NAE) to developers of Codexis core platform technology in directed evolution
- Establishment of research centers of excellence in Singapore and Budapest
- Completion of the first advanced biofuels company IPO in 2010
- Longstanding collaborative partnerships with global leaders including Shell, Merck, Pfizer and Chemtex
About Codexis, Inc.Codexis, Inc. is a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates. Codexis’ product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see www.codexis.com. Forward-Looking Statements This press release contains forward-looking statements relating to the Codexis business strategy referred to in this press release. (Legal to update language) Additional factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2012, including under the caption “Risk Factors.” Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts